Syngene sets up microbial facility as it expands biopharma-manufacturing capacity
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The sensors have been tested for their different level of strains like micro and large scale motion monitoring and have potential applications in biomedical devices, skin electronics, and minimally invasive surgery
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Price band in the range of Rs 933 to Rs 954
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
The study was conducted in patients with mild to moderate COVID-19
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Viruses evolve into new strains when there is a change to their genetic composition.
Subscribe To Our Newsletter & Stay Updated